SCHEMBL7036026

SCHEMBL7036026

CC(C#N)CN1CC2CC(C1)CN(CC(O)COc1ccc(S(=O)(=O)N(C)C)cc1)C2

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.45
MAPK1 P28482 4/20 0.41
USP2 O75604 3/20 0.41
LMNA P02545 2/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 2/20 0.39
HTT P42858 2/20 0.39
RAD52 P43351 1/20 0.39
KDM4E B2RXH2 2/20 0.39
GLA P06280 1/20 0.39
TSHR P16473 1/20 0.39
MAPT P10636 2/20 0.39
CASP2 P42575 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7033724 0.84 MEN1 (0.44) MAPK1USP2LMNAALDH1A1L3MBTL1
SCHEMBL6999528 0.82 MAPK1 (0.42) MAPK1USP2LMNAALDH1A1L3MBTL1
SCHEMBL6992494 0.82 KDM4E (0.41) KCNH2MAPK1USP2LMNAALDH1A1
SCHEMBL7032226 0.81 CACNA1G (0.52) KCNH2LMNAALDH1A1KMT2AMEN1
SCHEMBL7035045 0.81 L3MBTL1 (0.41) KCNH2MAPK1USP2LMNAALDH1A1
SCHEMBL7032240 0.80 MEN1 (0.39) KCNH2MAPK1USP2LMNAALDH1A1
SCHEMBL7025739 0.80 MAPK1 (0.41) KCNH2MAPK1USP2LMNAALDH1A1
SCHEMBL6989056 0.79 POLB (0.49) MAPK1USP2LMNAALDH1A1L3MBTL1
SCHEMBL6992942 0.78 KCNH2 (0.53) KCNH2MAPK1USP2LMNAALDH1A1
SCHEMBL6997257 0.78 ALDH1A1 (0.42) LMNAALDH1A1L3MBTL1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E KCNH2 7/4885MAPK1 1048/4885USP2 2530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.